Identification, selection and use of high curative potential t cell epitopes
AssigneeVerik Bio, Inc.
InventorsNancy Parenteau, Joseph Laning, Janet Young
Life of this patent
Estimating the term…
Loading patent…
AssigneeVerik Bio, Inc.
InventorsNancy Parenteau, Joseph Laning, Janet Young
Estimating the term…
A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprograming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.
A composition comprising an adjuvant and T-cell epitopes derived from leucine zipper protein 4 (LUZP4), comprising a sequence selected from SEQ ID NOs. 310, 312-337.
2-10. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.